Endocan or endothelial cell specific molecule-1 (ESM-1): A potential novel endothelial cell marker and a new target for cancer therapy

Sarrazin, Sandrine; Adam, Estelle; Lyon, Malcolm; Depontieu, Florence; Motte, Vincent; Landolfi, C.; Lortat‐Jacob, Hugues; Béchard, David; Lassalle, Philippe; Delehedde, Maryse

doi:10.1016/j.bbcan.2005.08.004

Cited by 245 publications

(318 citation statements)

References 87 publications

Supporting

Mentioning

292

Contrasting

Unclassified

Order By: Relevance

“…It serves also to distinguish between SIRS and sepsis with a specificity of 100%. However, no data exist for patients undergoing large cancer surgery, as cancer also upregulates endocan circulating levels (Sarrazin et al 2006). Moreover, endocan kinetic data in the course of sepsis are missing.…”

Section: Endocanmentioning

confidence: 99%

Biomarkers of endothelial dysfunction: can they help us deciphering systemic inflammation and sepsis?

2011

View full text Add to dashboard Cite

Section: Endocanmentioning

confidence: 99%

Biomarkers of endothelial dysfunction: can they help us deciphering systemic inflammation and sepsis?

2011

View full text Add to dashboard Cite

“…By RT-PCR, the authors showed that endocan and VEGF mRNA expressions were positively correlated . Large gene expression studies have previously shown that endocan overexpression was correlated with the overexpression of angiogenic molecules such as VEGF, VEGFR or c-met in various types of cancers including lung cancer (reviewed in Sarrazin et al, 2006). As VEGF induce a sustained increase in both endocan mRNA and protein in primary cultured human endothelial cells, endocan overexpression observed in lung tumor vessels may be considered as a consequence of local VEGF expression in tumor microenvironment.…”

Section: Endocan Overexpression In Cancermentioning

confidence: 99%

“…All the cultured human endothelial cells that were tested from different origins (including coronary, pulmonary artery dermal and capillary endothelial cells) and that were grown in serumrich culture media, have been shown to express endocan transcripts or proteins (reviewed in Sarrazin et al, 2006). However, highly vascular organs like brain, liver and heart were not identified as expressing endocan (Lassalle et al, 1996;Aitkenhead et al, 2002), suggesting that endocan is not expressed by resting endothelial cells and leading investigators to propose endocan as a marker of endothelial activation.…”

Section: Endocan As a Marker Of Endothelial Activationmentioning

confidence: 99%

Endocan as a Biomarker of Endothelial Dysfunction in Cancer

Sarrazin¹,

Claude-Alain²,

Delmas³

et al. 2010

J Canc Sci Ther

View full text Add to dashboard Cite

Endocan also called endothelial cell-specific-molecule-1 is a product of endothelial cells, highly regulated by vascular endothelial growth factor and expressed during the switch between dormant to fast-growing angiogenic tumors. No other molecule is currently known to be a read out of endothelial activation and dysfunction in tumor progression. We here reviewed the present knowledge about endocan that present clinical value as a tissue-and blood-based prognostic and potentially as a companion biomarker in cancer. By immunohistochemistry endocan was shown to be overexpressed into endothelial cells of small and large vessels in lung, kidney and brain tumors. High endocan serum levels were shown to be significantly correlated with the presence of metastasis and with limited survival in kidney and lung cancers. Moreover, endocan release by endothelial cells was in vitro modulated by addition of anti-angiogenic compounds. At a time where biomarkers are hugely needed to improve anti-angiogenic targeted treatments, endocan could be a pertinent biomarker to select patients and/or to clinically monitor the efficacy of cancer drugs. Through its awaited functional applications, endocan appears today as a promising biomarker to access to personalized medicine and to optimize therapy cost / benefit ratio.

show abstract

“…IdoA is an important component of the functional structure of endocan. In cancer patients, patients with sepsis and tissue samples of healthy volunteers, serum protein endocan is present in the form of a polysaccharide (1)(2)(3)(4). Studies of the HUVEC vascular endothelial cell model show that the endocan expression level is extremely low, which cannot meet the requirements of scientific research (4).…”

Section: Introductionmentioning

confidence: 99%

Endocan: A new marker for cancer and a target for cancer therapy

Yang

et al. 2015

Biomedical Reports

View full text Add to dashboard Cite

Abstract. Endocan, previously known as endothelial cell-specific molecule-1 (ESM-1), was cloned from the human umbilical vein endothelial cell cDNA library. Endocan is a novel ESM, and a 50 kDa soluble proteoglycan. Endocan is secreted into the blood as the soluble proteoglycan, which is the form in the presence of chondroitin sulfate. In normal tissues, chondroitin sulfate/dermatan sulfate proteoglycan is expressed by endothelial cells (such as lung and kidney) and is overexpressed in several carcinoma endothelial cells. There are studies that identified high endocan expression in lung cancer, uterine cancer, kidney cancer, liver cancer, brain glioblastoma, breast cancer and other tumors. Tumor prognosis, metastasis and angiogenesis were shown to be associated with endocan expression. The majority of investigators believe that endocan regulates the tumor by tumor-associated inflammation, angiogenesis, lymphangiogenesis, the tumor cells themselves and other aspects. Endocan may be a new target for cancer therapy.

show abstract

Endocan or endothelial cell specific molecule-1 (ESM-1): A potential novel endothelial cell marker and a new target for cancer therapy

Cited by 245 publications

References 87 publications

Biomarkers of endothelial dysfunction: can they help us deciphering systemic inflammation and sepsis?

Biomarkers of endothelial dysfunction: can they help us deciphering systemic inflammation and sepsis?

Endocan as a Biomarker of Endothelial Dysfunction in Cancer

Endocan: A new marker for cancer and a target for cancer therapy

Contact Info

Product

Resources

About